Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates
To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Cancer research - 71(2011), 20 vom: 15. Okt., Seite 6300-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
FitzGerald, David J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.12.2011 Date Revised 17.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-11-1374 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM212217704 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM212217704 | ||
| 003 | DE-627 | ||
| 005 | 20240417231951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-11-1374 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM212217704 | ||
| 035 | |a (NLM)21998010 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a FitzGerald, David J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.12.2011 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation, Myelomonocytic |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Bacterial Toxins |2 NLM | |
| 650 | 7 | |a CD22 protein, human |2 NLM | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 650 | 7 | |a CD33 protein, human |2 NLM | |
| 650 | 7 | |a Cd33 protein, mouse |2 NLM | |
| 650 | 7 | |a Exotoxins |2 NLM | |
| 650 | 7 | |a IL3RA protein, human |2 NLM | |
| 650 | 7 | |a Immunotoxins |2 NLM | |
| 650 | 7 | |a Interleukin-3 Receptor alpha Subunit |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-2 |2 NLM | |
| 650 | 7 | |a SDC1 protein, human |2 NLM | |
| 650 | 7 | |a Sialic Acid Binding Ig-like Lectin 2 |2 NLM | |
| 650 | 7 | |a Sialic Acid Binding Ig-like Lectin 3 |2 NLM | |
| 650 | 7 | |a Syndecan-1 |2 NLM | |
| 650 | 7 | |a immunotoxin HA22 |2 NLM | |
| 650 | 7 | |a 2NDX4B6N8F |2 NLM | |
| 700 | 1 | |a Wayne, Alan S |e verfasserin |4 aut | |
| 700 | 1 | |a Kreitman, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Pastan, Ira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 71(2011), 20 vom: 15. Okt., Seite 6300-9 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2011 |g number:20 |g day:15 |g month:10 |g pages:6300-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-11-1374 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2011 |e 20 |b 15 |c 10 |h 6300-9 | ||